论文部分内容阅读
目的观察紫杉醇联合替吉奥胶囊(维康达)方案治疗晚期胃癌的临床疗效及不良反应。方法 46例晚期胃癌患者采用以下方案化疗:替吉奥胶囊每天80 mg/m2,分2次,餐后口服,d1～d14;紫杉醇60 mg/m2,d1、d8、d15,静脉滴注3 h。28 d为1个周期,至少完成2个周期。按RECIST1.1标准评价客观疗效和不良反应。结果 46例患者均可以评价疗效。CR 3例(6.5%),PR 18例(39.1%),SD 14例(30.4%),PD 11例(23.9%),RR 45.6%,DCR 76.0%。中位疾病进展时间(mT-TP)为9.5个月,中位生存期(MST)为12.6个月。不良反应主要是骨髓抑制、胃肠道反应、脱发及口腔黏膜炎。结论紫杉醇联合替吉奥方案治疗晚期胃癌的疗效较好,不良反应可以耐受,值得进一步研究应用。
Objective To observe the clinical efficacy and side effects of paclitaxel combined with tegaserod (Vecona) in the treatment of advanced gastric cancer. Methods Forty-six patients with advanced gastric cancer were treated with the following regimen: Teglitazone 80 mg / m2 every day, twice daily, postprandial oral d1 to d14, paclitaxel 60 mg / m2, d1, d8 and d15 for 3 h . 28 d for 1 cycle, at least 2 cycles completed. According to RECIST1.1 standard evaluation of objective efficacy and adverse reactions. Results All the 46 patients could evaluate the curative effect. There were 3 cases of CR (6.5%), 18 cases of PR (39.1%), 14 cases of SD (30.4%), 11 cases of PD (23.9%), 45.6% of RR and 76.0% of DCR. Median disease progression time (mT-TP) was 9.5 months, and median survival (MST) was 12.6 months. Adverse reactions are mainly bone marrow suppression, gastrointestinal reactions, hair loss and oral mucositis. Conclusion The combination of paclitaxel and tegaserod for the treatment of advanced gastric cancer has good curative effect and adverse reactions can be tolerated. It is worth further study and application.